'A major issue in Major Depressive Disorder is the MTHFR polymorphism, with some references reporting as much as 80% of the US population having 1 variant form. EnLyte addresses these issues.' Towny Robinson, CEO, JayMac Pharmaceuticals.
Orlando, FL (PRWEB) September 16, 2014
The 27th installment of the Psych Congress meeting will take place in Orlando September 20-23. Exhibiting will be JayMac Pharmaceuticals, makers of the advanced generation folate therapy, EnLyte. This is the nation’s largest independent educational conference for medical professionals looking to increase their knowledge on mental health disorders.
This year's sessions include treatment resistant major depressive disorder, menopausal depression, and an entire day on maternal mental health. With these topics, EnLyte is sure to get a lot of attention, as more professionals and patients are looking for alternatives to standard antidepressants to treat these types of conditions, given the poor response rate and many side effects of typical SSRIs/SNRIs cited by the STAR*D Study. EnLyte is an affordable, natural rx. option for depression with a pregnancy category A safety rating. Folate therapy is recommended by both the APA and the APA Task Force on Complementary and Alternative Medicine as effective treatment for Major Depressive Disorder in combination with SSRI/SNRI therapy with low risk, favorable side effect profile, and general health benefits, and EnLyte is the most complete folate therapy on the market that meets USP standards for dissolution and degradation. This is the first year JayMac has participated in Psych Congress, and since it's launch, EnLyte has steadily gained loyalty in the Psychiatric community as a safe, effective, and affordable adjunctive choice in depression.
Dr. Andrew Farah, MD, Chief of Psychiatry of UNC, High Point Regional Health Systems and the co-inventor of EnLyte and JayMac CEO, Towny Robinson, will be at the JayMac booth-an excellent chance to have live Q and A between these experts and attendees.
EnLyte contains 16 mgs. of Delta Folate, plus b vitamin metabolite cofactors, as well as betaine, PS Gold omega 3s, zinc, magnesium, and vitamin C. It may be used as monotherapy or adjunctive therapy in mild, moderate, and severe depression, is paid by 75% of all payers, has an average insurance copay of $44, and is $55/month through mail order.
Learn more at http://www.EnLyteRx.Com.